Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

38.02 +0.50 (+1.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,503,170
Open 37.74
Bid (Size) 38.00 (1)
Ask (Size) 38.01 (50)
Prev. Close 37.52
Today's Range 37.57 - 39.11
52wk Range 21.62 - 39.54
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
The Smart Money Is Buying These 10 Stocks
Via Benzinga

Performance

YTD
+34.8%
+34.8%
1 Month
+5.9%
+5.9%
3 Month
+4.9%
+4.9%
6 Month
+39.8%
+39.8%
1 Year
+36.7%
+36.7%

More News

Read More
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For April 29, 2025
Via Benzinga
A Look Ahead: BridgeBio Pharma's Earnings Forecast
Via Benzinga
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Via The Motley Fool
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Via Benzinga
Topics World Trade
Exposures Tariff
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
Via Investor's Business Daily
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Competitive Analysis In The ATTR-CM Field
Via Talk Markets
Topics Stocks / Equities
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Via Benzinga
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Via Investor's Business Daily
BridgeBio Announces CFO Succession
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
What is the current price of BridgeBio Pharma, Inc. - Common Stock?
The current price of BridgeBio Pharma, Inc. - Common Stock is 38.02
When was BridgeBio Pharma, Inc. - Common Stock last traded?
The last trade of BridgeBio Pharma, Inc. - Common Stock was at 06/04/25 04:00 PM ET
What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 6.10B
How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
BridgeBio Pharma, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.